LEXINGTON, Mass., Aug. 09, 2023 — iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that the Company has added a new functionality to its proprietary iSpecimen Marketplace® platform to simplify how researchers find and acquire highly annotated, clinically collected remnant samples, which are leftover biospecimens from those collected for clinical or diagnostic purposes.
Historically, remnant samples have been sourced from hospital labs and are typically limited in terms of the types of samples and test data. With this update, the iSpecimen Marketplace now displays real-time remnant sample requests from researchers, enabling them to effectively source and obtain a wider offering of necessary remnants from a large number of suppliers within iSpecimen’s network. This includes suppliers that typically provide banked or prospective samples but may not be aware of requests for remnant materials. In this way, iSpecimen’s Marketplace provides researchers with more complex and well-annotated sample orders.
Additionally, since biorepository sites may have leftover samples stored from prospective collections, these sites may have more expansive data and can provide samples at a lower cost. The sites also generally have these samples stored on-location and are ready to ship, which streamlines workflow and improves sample order fulfillment speed.
“Our latest Marketplace enhancement enables us to address the ongoing issues in remnant sample procurement and streamline fulfillment timelines for both researchers and suppliers,” said Tracy Curley, iSpecimen’s CEO. “Now more than ever – and especially with the rise of precision medicine – researchers need highly specific samples and are often up against roadblocks when putting in these types of requests. Our technology is specifically designed to ease this burden and provide robust samples in a way that has never been more efficient.”
About iSpecimen
iSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.
Forward Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as “may,” “will,” “expect,” “intend,” “anticipate,” “believe,” “estimate” and “continue” or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information.
Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company’s filings with the Securities and Exchange Commission, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company’s forward-looking statements occurs, the Company’s business, financial condition and operating results may vary materially from those expressed in the Company’s forward-looking statements.
Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact:
Investor Contact
KCSA Strategic Communications
Phil Carlson / Erika Kay
iSpecimen@kcsa.com
Media Contacts
KCSA Strategic Communications
Raquel Cona / Shana Marino
iSpecimen@kcsa.com
